病灶内注射透明质酸酶治疗眶周黏液性水肿。
Periorbital myxedema treated with intralesional hyaluronidase.
作者信息
Lindgren Aleksandra L, Sidhu Sharleen, Welsh Kathleen M
机构信息
University of Queensland - Ochsner School of Medicine, 1524 Jefferson Highway, New Orleans, LA, USA.
Carson Tahoe Regional Medical Center, 1600 Medical Parkway, Carson City, NV, USA.
出版信息
Am J Ophthalmol Case Rep. 2020 May 25;19:100751. doi: 10.1016/j.ajoc.2020.100751. eCollection 2020 Sep.
PURPOSE
Periorbital myxedema is one the most challenging symptoms for patients with Graves' eye disease (GED). The treatment of this condition is complex and often unsatisfactory. This case demonstrates the use of intralesional hyaluronidase to treat cosmetically concerning periorbital myxedema.
OBSERVATIONS
Follow up showed no clinically significant recurrence of myxedema over one year.
CONCLUSION
Intralesional hyaluronidase represented an effective and safe treatment of periorbital myxedema in a patient with Graves' eye disease.
目的
眶周黏液性水肿是格雷夫斯眼病（GED）患者最具挑战性的症状之一。这种病症的治疗复杂且往往不尽人意。本病例展示了病灶内注射透明质酸酶治疗在美容方面令人担忧的眶周黏液性水肿的应用。
观察结果
随访显示黏液性水肿在一年多时间里无临床显著复发。
结论
病灶内注射透明质酸酶是治疗格雷夫斯眼病患者眶周黏液性水肿的一种有效且安全的方法。
Zotero 插件